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Abstract  
Background. It has been proposed that islet transplants comprised primarily of 
small rather than large islets may provide better graft function, due to their 
lower susceptibility to hypoxic damage. Our aim was to determine whether 
islet size correlated with in vivo graft function in islet transplant recipients with 
C peptide negative type 1 diabetes when islets have undergone pre-transplant 
islet culture.  
Methods. Human pancreatic islets were isolated, cultured for 24hours and 
infused by standardised protocols. 90 min-stimulated C-peptide 
concentrations were determined during a standard meal tolerance test 3 
months post-transplant. The islet isolation index (IEq/islet number) was 
determined immediately after isolation and again before transplantation (after 
tissue culture). This was correlated with patient insulin requirement or 
stimulated C-peptide.  
Results. Changes in insulin requirement did not significantly correlate with 
islet isolation index. Stimulated C-peptide correlated weakly with IEq at 
isolation (p=0.40) and significantly with IEq at transplantation (p=0.018). 
Stimulated C-peptide correlated with islet number at isolation (p=0.013) and 
more strongly with the islet number at transplantation (p=0.001). In contrast, 
the correlation of stimulated C-peptide and islet isolation index was weaker 
(p=0.018) and this was poorer at transplantation (p=0.034). Using linear 
regression, the strongest association with graft function was islet number 
(r=0.722, p=0.001). Islet size was not related to graft function after adjusting 
for islet volume or number.  
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Conclusion. These data show no clear correlation between islet isolation 
index and graft function; both small and large islets are suitable for 
transplantation provided the islets have survived a short culture period post-
isolation. 
 
Introduction 
Clinical islet transplantation is an effective treatment for stabilising glycaemic 
control in patients with type 1 diabetes complicated by severe hypo-
glycaemia. Unfortunately, numerous donor and retrieval factors, such as 
donor age, BMI, cold ischaemia time, collagenase lot, organ perfusion quality 
or retrieval team can influence the outcome of the islet isolation process and 
affect islet yields [1-6] whereas factors such as donor age have been shown 
to be importantant determinants of islet graft function [5, 7].  As a result, at 
best in leading clinical centres worldwide, only 50% of islet preparations are of 
sufficient quality and high enough yield for transplantation [2, 3, 8]. In addition 
early post-transplant islet destruction, variable engraftment, the nature of the 
immunosuppression used, and subsequent graft deterioration over time all 
contribute to variable long-term islet function [9-12]. Indeed it is widely 
accepted that less than 50% of transplanted islets survive the initial stage of 
engraftment [13-16]. Consequently, there has been considerable debate 
about the optimal composition of islet preparations used for transplantation. It 
has been long been established that total islet graft volume and islet number 
are critical for transplantation success[17-19], but more recently it has also 
been suggested that grafts comprising predominantly of small islets may be 
preferential due to their reduced susceptibility to hypoxia and central necrosis. 
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Indeed, a number of in vitro studies have shown that smaller islets have 
superior function compared to larger ones [20-24]. However, data confirming 
this in clinical studies are more limited. Lehmann et al [2007] acknowledged 
the importance of the factors discussed above for islet success and 
transplantation outcomes but also [15] reported that better function was 
associated with grafts comprising of smaller islets in simultaneous islet-kidney 
transplant recipients; however there were only seven recipients in the study, 
all in end-stage renal failure. Importantly, the islets used within that study 
were transplanted ‘fresh’ following islet isolation, rather than having the 
benefit of undergoing a period of islet culture.  A larger study in autologous 
islet recipients following pancreatectomy also supported this conclusion, 
although in this study, grafts of marginal islet mass were often transplanted 
[25]. Our own observation[26] however, is that provided larger islets survive a 
period of pre-transplant islet culture, they can confer advantages over smaller 
islets in terms of graft function and graft longevity. To investigate this 
discrepancy, we aimed to correlate islet size (pre- and post-culture) with in 
vivo measures of graft function in all islet transplant recipients receiving their 
first transplant in our islet transplant programme over a 6 year period. 
 
Methods 
Human pancreases were retrieved with appropriate consent and ethical 
approval from 25 deceased multi-organ donors (15 female and 10 male). 
Median (range) donor age was 49 (34-60 yrs) and median donor BMI 29 (23-
37) kg/m2. Following standardised procurement, the pancreas was 
transported in University of Wisconsin solution at 4oC to the Diabetes 
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Research & Wellness Foundation (DRWF) Human Islet Isolation Facility in 
Oxford. Median (range) cold ischaemia time was 6.7 hours (4-10.5 hours). 
Pancreatic islets were isolated using a standard protocol as described 
previously [27]. After infusion and digestion with Collagenase NB 1 and 
neutral protease NB enzyme blend (Serva, Heidelberg, Germany), islets were 
purified using a ficoll-based continuous density gradient and quality-assessed 
(for sterility, viability, purity and yield) as previously described [28-30]. Islet 
number and size were determined in dithizone stained islet samples by visual 
microscopic inspection by comparing the stained islet- particles in multiple 
representative samples against a size graticule ranging from 50->400 µM in 
size. Each preparation was resuspended in 150-200 mL CMRL based culture 
media and multiple samples collected whilst in continuous suspension. The 
islets in the samples were visualised by dithizone staining under a light 
microscope and the size of each islet in the sample determined by 
comparison with a calibrated graticule in the microscope objective; the total 
number of islets in each sample and their sizes were recorded  Islet 
preparations were then cultured for a minimum of 24 hours in  the CMRL 
media in a humidified atmosphere at 37oC before a full reassessment. Islets 
were then transplanted either locally or at a satellite transplant centre. If 
allocated to a recipient at a satellite transplant centre [31] the islet preparation 
was transported by road (maximum journey time 8 hours) in cooled standard 
500 ml blood transfusion bags with a temperature monitor [27, 28]. Following 
confirmation of satisfactory temperature maintenance during transport 
together with confirmation of maintained islet integrity and viability from a 
side-arm islet sample, islets were transplanted directly from the transport bag.  
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Only recipients undergoing their first islet transplant were included in this 
study (n=25). In all cases, islets were transplanted by percutaneous trans-
hepatic delivery into the portal vein under radiological visualisation. All 
patients received a minimum of 5000 Islet Equivalents (IEq) per kg body 
weight (median 5500 IEq/kg). Peri-transplant, recipients were placed on an 
intravenous glucose / insulin sliding scale and received a heparin infusion 
according to published protocols [32].  
Each patient received a standard immuno- suppression protocol comprising 
alemtuzumab (Campath) induction 30mg prior to and on day 1 after 
transplant; tacrolimus at 0.05mg/kg/day titrated to a serum trough level of 8-
12 ng/ml; mycophenolate mofetil  (500 mg BD) and total daily insulin 
requirements were monitored at routine intervals. Intensified insulin regimens 
were continued in all post-discharge, with the goal being maintenance of 
optimal glycemic control. 
In a sub-group of the recipients (n=18), 90 min-stimulated C-peptide 
concentrations were determined during a standard meal tolerance test 3 
months post-transplant. Grafts with primary non-function as defined by a 
stimulated C-peptide level < 50 pmol/L were excluded from all subsequent 
analysis. Assessment of stimulated C- peptide was made at three months 
post-transplantation as an indicator of early graft function. It was also done at 
this time to avoid any complicating effects of a subsequent second transplant 
which is carried out in the UK islet transplant programme [31].The beta score 
was also determined for each transplant recipient at 3 months post transplant 
as described by Ryan et al [33].  
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For each islet preparation transplanted, the islet isolation index (IEq/islet 
number) was calculated; the total IEq of the preparation is the internationally 
agreed standard for the total volume of the islet graft. The islet isolation index 
therefore is a measure of the average size of each islet within the graft, with 
and index of 1 indicating an average islet size of 150 µM in diameter. Islet 
isolation index was related to 3 variables of graft function in transplant 
recipients; a) the change in insulin requirement (before vs 3 months after 
transplant) ,b) the 90 minute stimulated C-peptide level taken 3 months post-
transplant and c) the beta score at 3 months post-transplant [33]. 
 
For statistical analysis, data were tested for normalcy and are presented as 
means ± standard deviations (SD) or median (range) depending on data 
distribution. Groups were compared using paired Student’s t-test when 
appropriate. Correlations were assessed using Pearson’s correlation 
coefficient. Linear regression was performed with pre- and post-culture islet 
isolation variables (age, bmi, CIT, viability, purity, IEQ/kg, Islet number/ kg 
and islet isolation index) as exposure variables and change in insulin dose or 
stimulated C-peptide as outcome variables. Multiple regression was 
conducted to assess the impact of islet isolation outcomes on stimulated C-
peptide, adjusting for donor age and BMI, or on Beta Score, adjusting for 
donor age and prep purity. Final multiple regression models were fitted using 
backward stepwise elimination of candidate variables. p<0.05 was considered 
statistically significant.. Finally, a power calculation was carried out assuming 
p<0.05, a sample size of 25, and α=0.05. To obtain an R value=0.5, the power 
was 0.73; R value 0.6, power was 0.9 and  an R value 0.7, the power was 
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0.98.  Data analysis was performed using SPSS, Version 20 & 24 (2011). IBM 
Corp, Armonk, NY.  
 
 
Results 
Donor and islet preparation characteristics are summarised in Table 1. 
Immediately post-isolation, the islet yield (mean±SD) was 454,800±190,900 
IEq with a mean islet number of 232,320±114,060 islets, purity ranged from 
50-90% and viability was ≥ 75% in all cases. After 24 hours in culture, the islet 
number had significantly reduced to 197,300±91,200 islets (p=0.013, paired t-
test) whereas the small reduction in IEq to 408,600±126,700 was not 
significant. Prior to transplantation, patients required a mean of 31.5±13.4U 
insulin per day (0.48±0.18U/kg body wt/ day), which was reduced by 
17.1±9.9U/day to 15.3±14.0U/day (0.22±0.18U/ kg body wt/ day)  at 3 months 
post-transplant. The mean stimulated C-peptide concentration during a meal 
tolerance test at 3 months post-transplant was 624±524 pmol/L (Table 1).  
 
The change in insulin requirement before and 3 months after transplant was 
correlated with islet size as assessed by the islet isolation index of the 
transplanted islet preparation (Figure 1). There was no significant correlation 
with changing islet isolation index of the transplanted islets and graft function; 
either absolute change in insulin requirement (r = -0.005, p=0.49), percentage 
change in insulin requirement (r = -0.27, p=0.099) or insulin change per kg 
body weight of the recipient (r = -0.15, p=0.24). The change in insulin 
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requirement also correlated poorly with IEQ (r = 0.11, p=0.49) or IEQ/kg body 
weight (r = 0.05, p=0.4) (data not shown). 
 
In contrast, stimulated C-peptide levels at 90 minutes during a meal tolerance 
test were significantly correlated with the number of islets in the graft 
(p=0.004, r = 0.605), and the strongest correlation determined was with the 
number if islets in the graft per kg body weight (r = 0.722, p<0.001, figure 2B). 
In contrast, the correlations with IEq (r = 0.17, p=0.25) or IEq per kg recipient 
body weight (r = 0.494, p=0.018) were poorer (figure 2A). When plotted 
against the islet isolation index of the transplanted islets, the correlation with 
stimulated C-peptide remained significant (r= -0.416, p=0.043) as did 
stimulated C-peptide per IEq per kg body weight of the recipient (r = -0.439; 
p=0.034, Figure 2C & D). As the islet yield and number had changed during 
culture from the values measured at isolation, we also determined correlations 
for stimulated C-peptide with parameters measured immediately after 
isolation. The correlation of stimulated C-peptide with islet number was 
significant (Figure 3B, r = 0.526; p=0.013) but poorer than that determined at 
transplantation whereas the correlation with IEq at isolation was weak (Figure 
3A, r = -0.056; p=0.411). The correlation of stimulated C-peptide per IEQ per 
kg body weight however, was more significant with the islet isolation index of 
the preparations determined immediately after isolation (Figure 3C, r = -0.495; 
p=0.018) than that determined at transplantation. 
 
We assessed the strength of univariable and multivariable-adjusted 
associations between islet isolation yield parameters, purity, viability,  donor 
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variables (age, bmi, CIT) and 90-minute stimulated C-peptide levels using 
linear regression. These data confirmed the observation that the factor most 
strongly associated with graft function in univariable analysis was the number 
of islets in the graft (p=0.001; Table 2). In a model including both total islet 
volume (IEq/kg) and islet size (Isolation index; IEq/ Islet number) total islet 
volume and donor age were related to 90-minute stimulated C-peptide levels 
(islet volume, β =0.101, p=0.019; donor age  β=-26.0, p=0.034, Table 2). In a 
model including both islet number (number/kg) and islet size only islet number 
was related to 90-minute stimulated C-peptide levels (β =0.19, p=0.001; Table 
2). Islet size was not related to graft function after adjusting for total islet 
volume or islet number or any of the other variables analysed..  
 
Islet isolation index, islet volume and islet number at transplantation were also 
correlated with the beta score as another measure of graft function at 3 
months post transplant (data not shown). The correlation of the beta score 
with islet isolation index at transplantation (r=-0.584, p=0.011) was poorer 
than that with islet number (r=0.784, p=0.001). Univariate linear regresson 
with factors - islet isolation variables and donor variables with beta score 
showed that islet number/ kg (p=0.026), islet isolation index (p=0.022) and 
islet purity significantly (p=0.027) affected this measure of graft function. 
Further multiple regression analysis however indicated that both islet 
number/kg (p=0.032) and islet purity (p=0.38) but not islet isolation index had 
a signifcant effect in the final model of the analysis.  
 
. 
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Discussion  
In this study, we tested the existing hypothesis that islet grafts comprising 
predominantly smaller islets have superior function compared with those 
composed of large islets. We have done this by correlating islet size within 
transplanted grafts with the post-transplant metabolic outcomes of the 
recipients. Several studies using experimental animal models have previously 
shown that smaller islets are potentially more beneficial as islet grafts. Smaller 
islets have been shown to have improved nutrient supply, with larger islets 
depleted of both oxygen and glucose at the core [34, 35]. Smaller islets also 
exhibit improved insulin secretory function in vitro, exhibit a higher vascular 
density and function preferentially in transplant models [20-24]. Studies with 
human islets in vitro also reproduce some of these results; small human islets 
were shown to be less susceptible to hypoxia and had improved secretory 
function compared with large islets [15, 36].  
 
However, studies investigating whether the hypothesis is born out in allo-
transplant recipients of islet grafts have been limited. Lehmann et al [2007] 
[15] correlated islet size with stimulated C-peptide in 7 simultaneous islet- 
kidney transplant recipients with type 1 diabetes. This study showed that 
increasing the number of islets in the graft significantly correlated with graft 
function and critically, the most significant correlation was found between islet 
isolation index and stimulated C-peptide per kg body weight of the recipient. 
The authors argued that correction for islet size proved to be the best 
predictor of graft function with 89% of the variability (as indicated by the 
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correlation R2) being accounted for by the islet isolation index parameter. 
However the authors [15] recognised that their findings should be confirmed in 
a larger series of islet transplants. The present study was undertaken to do 
this. Here we report on two parameters of islet function in a larger cohort of 
islet transplant recipients; reduction in insulin requirement per day and 
stimulated C-peptide levels during a meal tolerance test. Neither of the 
parameters analysed show convincing correlation with the islet isolation index.  
There was no significant correlation with changes in patient insulin 
requirement in absolute terms or per kg body weight or when expressed as % 
change. Nor did the present study reproduce the findings of Lehmann et al 
[2007] [15], as the most significant correlation we found was between the 
number of islets in the graft and graft function as measured by stimulated C-
peptide. When the correction for islet size was included, the correlation was 
poorer and R2 reduced with only 19.3% of the variability accounted for by this 
parameter. 
 
Two factors may contribute to the different findings in our study compared 
with those of Lehmann et al [2007] [15]. First, their study was in patients 
undergoing simultaneous islet kidney transplants, whereas all our patients 
received islet transplants alone. Second, their observations were made using 
islets that had not undergone the benefit of a period of pre-transplant islet 
culture [37].  In the UK islet transplant programme, all islet preparations 
considered for transplantation undergo a minimum of 24 hour culture prior to 
transplant [27]. Using this protocol, any marginal grafts susceptible to hypoxic 
damage and leading to declining viability are screened out and therefore do 
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not proceed to transplantation. When islets are transplanted immediately after 
isolation or where only the immediate post-isolation characteristics (of yield 
and viability) are used to decide suitability for transplantation, declining or 
marginal grafts are potentially transplanted. As large islets are particularly 
susceptible to central necrosis, it can be postulated that when islets are 
transplanted immediately after isolation, it is the large islets that are 
particularly vulnerable to destruction, whereas large islets that are 
transplanted after surviving a period of islet culture are primarily robust and 
fully viable. Furthermore, the culture process itself may promote an adaptive 
or remodelling process in the islet preparation in which susceptible islets are 
selectively lost. Changes in islet morphology (rounding up) during culture and 
the significant reduction in islet number after culture in the present study is 
evidence of just such a process. We have also recently shown that short-term 
tissue culture ameliorates the destruction of human islets by IBMIR [38]. Thus 
it is possible that islets cultured for short periods prior to transplant are 
effectively preconditioned and any correlation between islet size and function 
in grafts is lost or reduced. In the present study the correlation of islet isolation 
index and graft function was stronger in freshly isolated islets compared to 
islets cultured for a minimum of 24 hours, at transplant. 
 
In addition, it may be the case that there are too many other confounding 
donor and recipient factors which over-ride any effect of islet size in 
determining graft function [25]. Suszynski et al [2014] [25] argued that islet 
auto-transplant patients offered a good model for studying the effect of the 
size of islets in the graft as these patients are uncompromised by factors such 
16 
 
as auto-immunity, prolonged diabetic environment [39]  and possibly IBMIR 
[16, 40]. In a cohort of 58 patients receiving islet auto-transplants after 
pancreatectomy for chronic pancreatitis, the islet isolation index correlated 
with the change in insulin requirement and insulin independence rates in the 
patients [25].  
 
Although the number of observations we present here is significantly (3 fold) 
greater that those reported by Lehmann et al[15], our analysis indicates that 
this retrospective study is still underpowered. Unfortunately the number of 
patients available to study has been limited by the practice in the UK islet 
transplant programme to retransplant islet recipients within 6 months of 
receipt of the first graft [31]. The effect of a second islet graft to potentially 
change the mean islet size transplanted in the recipient makes the analysis 
carried out in the present study impossible. 
 
Another theoretical limitation of the present study is that the method used to 
determine islet size in the graft samples may be less accurate than 
computational methods [37] which may capture more of the population of 
smaller islets during analysis. In the present study, islet sizes were 
determined by inspection and comparison using a graticule following 
microscopic visualisation. Our methodology has been agreed and validated 
between the participating islet isolation laboratories operating within the UK 
islet transplant programme. However, there is no evidence of a significant 
difference in the size distribution of islets in our study compared with the study 
by Lehmann et al [2007] [15], since the range of islet isolation indices here 
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(0.8-4.2) overlap almost completely with those which they reported (0.75-3.3) 
[15].  
 
Finally, it is important to note that changes in insulin requirement as a 
measure of graft function are less robust than stimulated C-peptide 
measurements. The latter is a positive output, directly measuring graft 
function whereas changes in insulin requirement are indirect and may not be 
necessarily linearly responsive to graft size. This less objective parameter 
however, has been used as the indicator of islet graft function in previous 
studies on islet transplant recipients [25, 41]. 
 
In summary, our study found no clear correlation between islet isolation index 
and islet graft function in recipients receiving islets that had been cultured 
prior to implantation. These data therefore do not support the hypothesis that 
smaller islets have better function when used in clinical islet transplantation; 
large islets are equally suitable provided they have undergone and survived a 
short period of culture post-isolation. 
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Table 1 Donor and recipient characteristics and islet preparation data  
Data are presented as mean±SD except for donor characteristics which are 
median (range). 
 
 
Donor Characteristics (N=25)  
Age (years) 49 (34-60)  
BMI (kg/m2) 29 (23-37) 
CIT (hours) 6.5 (4-10.5) 
  
Islet Preparation Characteristics (N=25)  
Isolation Yield (IEq) 454,800±190,900 
Isolation number (islet particles) 232,320±114,060 
Isolation Purity 74±12 
Isolation Viability  84.6±8.8 
Transplant Yield (IEq) 408,600±126,700 
Transplant number (islet particles) 197,300±91,200 
Transplant Purity 74±12 
Transplant Viability  85.6±8.4 
  
Recipient Characteristics (N=25)  
Weight (kg) 66±11.2 
IEq transplanted/ kg body weight 6340±2323 
Insulin requirement before TX (U/day) 31.5±13.4 
Insulin requirement after TX (U/day) 15.3±14.0 
Stimulated C-peptide (pmol/L) 624±524 
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Table 2 Univariate and multivariate relationships between islet isolation 
variable and 90-minute stimulated C-peptide levels at 3 months. Variables 
with p < 0.25 in the univariate analysis were put forward into the backward 
stepwise multiple regression models. For multiple regression, the first and 
final models are reported. 
 
Islet isolation variables ß (95% CI) P value 
Univariate models   
   Age -24.77 (-52.17 to 2.64) 0.074 
   BMI 48.87 (-23.71 to 121.46) 0.174 
   CIT 64.82 (-123.07 to 252.71) 0.477 
   Viability 20.42 (-46.62 to 87.45) 0.529 
   Purity 9.34 (-7.50 to 26.17) 0.258 
   IEQ/kg 0.10 (0.01 to 0.20) 0.039 
   Islet number/kg 0.19 (0.09 to 0.29) 0.001 
   Isolation index (IEQ/Islet 
number) 
-227.14 (-521.23 to 66.96) 0.122 
   
Multiple regression models   
 
    Including IEQ/kg and Islet number/kg 
First Model (F = 4.70 (4,14), P = 0.013, R2 = 0.573) 
   Age -12.37 (-38.15 to 13.41) 0.321 
   BMI 30.53 (-29.66 to 90.73) 0.295 
   IEQ/Kg 0.01 (-0.11 to 0.13) 0.824 
   Islet number/Kg 0.16 (-0.01 to 0.32) 0.054 
Final model (F = 15.25 (1, 17), P = 0.001, R2 = 0.473) 
   Islet number/kg 0.19 (0.09 to 0.29) 0.001 
   
   Including IEQ/kg and isolation index 
First model (F = 3.12 (4,14), P = 0.050, R2 = 0.471) 
   Age -19.10 (-46.86 to 8.67) 0.162 
   BMI 17.63 (-48.82 to 84.07) 0.578 
   IEQ/kg 0.10 (0.01 to 0.19) 0.033 
   Isolation index (IEQ/Islet 
number) 
-123.92 (-409.58 to 161.74) 0.368 
Final model (F = 5.828 (2, 16), P = 0.013, R2 = 0.421) 
   Age -25.97 (-49.77 to -2.17) 0.034 
   IEQ/kg 0.11 (0.02 to 0.19) 0.019 
   
    Including Islet number/kg and isolation index (IEQ/Islet number) 
First model (F = 5.510 (4,14), P = 0.007, R2 = 0.612) 
   Age -15.22 (-38.93 to 8.50) 0.190 
   BMI 35.84 (-20.17 to 91.84) 0.192 
   Islet number/kg 0.211 (0.08 to 0.34) 0.003 
   Isolation index (IEQ/Islet 
number) 
170.07 (-133.74 to 473.87) 0.250 
Final model (F = 5.510 (4,14), P = 0.007, R2 = 0.612) 
   Islet number/kg 0.19 (0.09 to 0.29) 0.001 
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Figure Legends 
Figure 1. Change in insulin requirement per day (A) or % change /day (B) or per 
kg body weight /day (C) in relation to islet isolation index of the islet graft. 
Figure 2. Correlation of stimulated C-peptide with the number IEQ (A), islets (islet 
particles) (B), or islet isolation index (C) or stimulate C-peptide / kg wt (D) at 
transplantation 
Figure 3. Correlation of stimulated C-peptide with the number of IEQ (A), number 
of islets (islet particles (B) or islet isolation index (C ) at isolation 
Figure 1. Change in insulin requirement per day (A) or % change /day (B) or per kg 
body weight /day (C) in relation to islet isolation index of the islet graft.  
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Figure 2. Correlation of stimulated C-peptide with the number IEQ (A), islets (islet 
particles) (B), or islet isolation index (C) or stimulated C-peptide / kg wt with islet 
isolation index (D) at transplantation 
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Figure 3. Correlation of stimulated C-peptide with the number of IEQ (A), number of 
islets (islet particles (B) or islet isolation index (C ) at isolation 
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